OrbiMed

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe, rare muscle disorders with significant unmet medical need. It employs a holistic drug discovery approach targeting the muscle as an organ, utilizing its proprietary platform to identify precision medicines regulating key proteins in muscle tissue.

TriSalus Life Sciences specializes in developing precision infusion systems for interventional radiology, focusing on targeted drug delivery to treat liver cancer and other solid tumors. The company's flagship products include the Surefire precision infusion systems designed for lobar, segmental, and super-selective infusions, as well as guiding catheters. TriSalus also develops Pressure Enabled Drug Delivery (PEDD) infusion systems and investigational agents like nelitolimod to enhance immune response in cancer treatment.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe, rare muscle disorders with significant unmet medical need. It employs a holistic drug discovery approach targeting the muscle as an organ, utilizing its proprietary platform to identify precision medicines regulating key proteins in muscle tissue.

Founded in 2019, Enliven Therapeutics is a precision oncology company based in Boulder, Colorado. It focuses on developing small molecule therapies to extend and improve patient lives by targeting clinically validated biological targets with industry-leading chemistry.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe, rare muscle disorders with significant unmet medical need. It employs a holistic drug discovery approach targeting the muscle as an organ, utilizing its proprietary platform to identify precision medicines regulating key proteins in muscle tissue.

Founded in 2019, Enliven Therapeutics is a precision oncology company based in Boulder, Colorado. It focuses on developing small molecule therapies to extend and improve patient lives by targeting clinically validated biological targets with industry-leading chemistry.

Cerapedics, Inc. is an orthobiologics company specializing in the development and commercialization of innovative synthetic small peptide technologies for bone healing. Founded in 2000 and headquartered in Westminster, Colorado, with an additional office in Denver, the company offers products such as i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural healing process in orthopedic applications, and i-FACTOR+ MATRIX for surgical implantation. Cerapedics focuses on creating biomimetic solutions, specifically its proprietary small peptide molecule (P-15), aimed at improving outcomes in spinal fusion surgery and other orthopedic procedures. The company's technology strives to provide safer and more predictable bone formation compared to traditional bone growth factors.

Cerapedics, Inc. is an orthobiologics company specializing in the development and commercialization of innovative synthetic small peptide technologies for bone healing. Founded in 2000 and headquartered in Westminster, Colorado, with an additional office in Denver, the company offers products such as i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural healing process in orthopedic applications, and i-FACTOR+ MATRIX for surgical implantation. Cerapedics focuses on creating biomimetic solutions, specifically its proprietary small peptide molecule (P-15), aimed at improving outcomes in spinal fusion surgery and other orthopedic procedures. The company's technology strives to provide safer and more predictable bone formation compared to traditional bone growth factors.

Cerapedics, Inc. is an orthobiologics company specializing in the development and commercialization of innovative synthetic small peptide technologies for bone healing. Founded in 2000 and headquartered in Westminster, Colorado, with an additional office in Denver, the company offers products such as i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural healing process in orthopedic applications, and i-FACTOR+ MATRIX for surgical implantation. Cerapedics focuses on creating biomimetic solutions, specifically its proprietary small peptide molecule (P-15), aimed at improving outcomes in spinal fusion surgery and other orthopedic procedures. The company's technology strives to provide safer and more predictable bone formation compared to traditional bone growth factors.

Cerapedics, Inc. is an orthobiologics company specializing in the development and commercialization of innovative synthetic small peptide technologies for bone healing. Founded in 2000 and headquartered in Westminster, Colorado, with an additional office in Denver, the company offers products such as i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural healing process in orthopedic applications, and i-FACTOR+ MATRIX for surgical implantation. Cerapedics focuses on creating biomimetic solutions, specifically its proprietary small peptide molecule (P-15), aimed at improving outcomes in spinal fusion surgery and other orthopedic procedures. The company's technology strives to provide safer and more predictable bone formation compared to traditional bone growth factors.